Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 59 months~* Weight ≥ 5 kg~* Mono-infection with P. falciparum detected by microscopy~* Parasitic density between 2,000 and 200,000 asexual forms /µL of blood~* Axillary temperature ≥ 37.5°C or history of fever during the previous 24 hours~* Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule (home is within one hour of walk from the outpatient department, no near-term travel plans, etc.)~* Consent of a parent or guardian who is at least 18 years of age.~Exclusion Criteria:~* Presence of general danger signs as defined by the WHO,~* Presence of signs of severe malaria according to the definitions of WHO,~* Severe anemia (haemoglobin \<5 g/dL),~* Known history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia,~* Family history of sudden death or of congenital prolongation of corrected QT interval,~* Use of antiarrhythmics or neuroleptics,~* Known history of hypersensitivity to any of the study medications,~* Severe malnutrition (defined as a weight-height ratio of \< -3 z-score according to the 2006 WHO reference (20) and / or a mid-upper arm circumference lower than 115 mm and / or the presence of symmetrical oedema of the feet),~* Presence of a febrile condition due to a disease other than malaria (i.e. measles, acute lower respiratory tract infection, otitis media, tonsillitis, abscess, severe diarrhoea with dehydration, etc.)~* History of a full treatment course with one of the three study drugs in the past 28 days. The prior incomplete intake of one of the three study drugs or prior intake of antimalarial drugs not being tested in the study does not exclude a patient from participating in this study. However, information on these previous treatments will be carefully recorded.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Artesunate-amodiaquine (Type: OTHER): Efficacy estimates at 95%
- Dihydroartemisinin-piperaquine (Type: OTHER): Efficacy estimates at 95%
- Artemether-lumefantrine (Type: OTHER): Efficacy estimates at 95%

Based on this trial design, predict the completion outcome and termination type (if applicable).